Gyrase inhibitors

1. A compound having the structure of Formula I

wherein

Y is N;

Z is CR 5 ;

R 5 is methyl, C(O)CH 3 , C(O)NH 2 , CH 2 OH, CF 3 , CN, CHF 2 , CHO, Cl or Br;

L is O, S, NR 7 , SO 2 , or CR 8 R 9 ;

R 7 is H or C 1-3 alkyl;

R 8 and R 9 are each independently H or C 1-3 alkyl;

R 2 is H, COOCH 2 CH 3 , CH 3 , CH 2 CH 3 or a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue wherein the hydrocarbyl residue comprises at least one aryl or heteroaryl moiety;

R 4 is

a) an inorganic residue selected from the group consisting of H, halo, NH 2 , SH, SO 2 H, NHOH, SO 3 H, SO 2 NH 2 , and NHSO 2 NH 2 ,

b) an aryl C5-14 or heteroaryl C1-14 moiety substituted with 0-10 substituents selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkylaryl, NH-aroyl, arylacyl, heteroarylacyl, halo, —O, OR′, NR′ 2 , SR′, SOR′, SO 2 R′, OCOR′, N-alkyl-OR′, CONR′OR′, NR′COR′, NR′CONR′ 2 , NR′COOR′, OCONR′ 2 , OR′, NR′ 2 , COOR′, alkyl-OOR′, SO 3 R′, CONR′ 2 , CONR′ 2 OH, SO 2 NR′ 2 , NR′SO 2 NR′ 2 , CN, CF 3 , or NO 2 , wherein each R′ is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two of said substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-14 members, and said substituents can only be —O if R 4 contains N,

c) alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkylaryl, alkenylaryl, alkynylaryl, heteroalkylaryl, heteroalkenylaryl, or heteroalkynylaryl moiety substituted with 0-10 substituents selected from the group consisting of aryl, haloaryl, arylalkyl, arylalkenyl, arylalkynyl, haloaryl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, acyl, aroyl, NH-aroyl, arylacyl, heteroarylacyl, halo, —O, ═O, ═NH, OR″, NR″ 2 , SR″, SOR″, SO 2 R″, OCOR″, CONR″OR″, NR″COR″, NR″CONR″ 2 , NR″COOR″, NR″COCOOR″, OCONR″ 2 , COOR″, SO 3 R″, CONR″ 2 , CONR″ 2 OH, SO 2 NR″ 2 , NR″SO 2 R″, NR″SO 2 NR″ 2 , CN, CF 3 , or NO 2 , wherein each R″ is independently H, optionally substituted alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, or halo forms thereof, and wherein two of said substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-14 members, and said substituents can only be —O if R 4 contains N, or

d) OR″′, NR″′ 2 , or OSO 2 R″′, wherein R″′ is an aryl C5-14 or heteroaryl C1-14, moiety substituted with 0-10 substituents selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkylaryl, NH-aroyl, arylacyl, heteroarylacyl, halo, —O, OR′, NR′ 2 , SR′, SOR′, SO 2 R′, OCOR′, N-alkyl-OR′, CONR′OR′, NR′COR′, NR′CONR′ 2 , NR′COOR′, OCONR′ 2 , COOR′, alkyl-OOR′, SO 3 R′, CONR′ 2 , CONR′ 2 OH, SO 2 NR′ 2 , NR′SO 2 NR′ 2 , CN, CF 3 , or NO 2 , wherein each R′ is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two of said substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-14 members, and said substituents can only be —O if R 4 contains N,

optionally wherein R 5 and R 4 together join to form a fused ring; and

R 6 is ethyl;

or a pharmaceutically-acceptable salt thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Y is N; and

L is O, S, NH, SO 2 or CH 2 .

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is CR 5 , wherein R 5 is selected from the group consisting of Cl, Br, and methyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 comprises at least one aryl or heteroaryl moiety.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the at least one aryl or a heteroaryl moiety of R 2 is directly linked to L.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the aryl or heteroaryl moiety of R 2 comprises at least one moiety selected from the group consisting of phenyl, pyrido[2,3-b]pyrazine, pyridyl, thiazole, quinoline, pyridazine, pyrimidinedione, pyrido[2,3-d]pyrimidinedione, pyrimidine, [1,2,3]triazolo[4,5-b]pyridine, oxazole, benzotriazine, furo[3,2-b]pyridine, thiazolo[5,4-b]pyridine, pyrazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, pyrido[3,2-d]pyrimidine, 1,5-naphthyridine, quinolone, quinazoline, and quinoxoline.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L-R 2 is selected from the group consisting of

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is

10. A compound which is

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound of claim 10 , or a pharmaceutically acceptable salt thereof.

13. A method of making a compound of claim 1 , or a pharmaceutically acceptable salt thereof, comprising deprotecting a protected form of a compound of Formula I wherein Z is C-halo.

14. The method of claim 13 comprising, before the deprotecting step, halogenating a protected form of the compound of Formula I wherein Z is CH to form a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Z is C-halo.

15. A method of claim 13 comprising halogenating a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein Z is CH to form a compound of Formula I, wherein Z is C-halo.